Moreover, a phase Ib clinical trial has evaluated the combination of the ALK inhibitor crizotinib with standard therapy in newly diagnosed glioblastoma patients, suggesting that targeting the MDK‐ALK axis may offer a new therapeutic strategy to overcome drug resistance.57 Here, MDK is linked to glioblastoma.